25 apr: Klassiske fejl når du investerer din pension - 1
30 apr: Kursfald oplagt købsmulighed i Novozymes
25-04-2012 13:40:00

National Oilwell 1Q Net Jumps 49% As Field Activity Ramps Up

Relateret indhold

DOW JONES NEWSWIRES

National Oilwell Varco Inc.'s (NOV) first-quarter earnings rose a stronger-than-expected 49% on broad growth in all the company's main business segments.

The company's earnings have surged over the past year as oil-and-gas producers boost their capital expenditures, often spending heavily on complex equipment that can extract harder-to-reach reserves through unconventional means like hydraulic fracturing and horizontal drilling.

Producers are now poised to move much of their spending in North America to areas that yield more oil and natural-gas liquids instead of cheap natural gas--a shift that could generate yet more demand for National Oilwell's products.

Chairman and Chief Executive Pete Miller said the company's petroleum services and supplies unit performed "exceptionally well" in the latest quarter as high levels of oilfield activity spurred demand across the company's businesses.

The company has grown to be become the sector's dominant equipment maker through mergers, including a deal for NKT Flexibles, a joint venture between NKT Holding A/S (NKT.KO) and Norwegian Subsea 7 SA (SUBC.OS) valued at about $672.6 million when it was disclosed in February.

National Oilwell this month unveiled yet another acquisition, agreeing to buy Schlumberger Ltd.'s (SLB) Wilson business, which distributes pipe, valves and other products to the oil patch. Terms of that deal, which will vastly expand National Oilwell's footprint, were not disclosed.

National Oilwell reported a profit of $606 million, or $1.42 a share, up from $407 million, or 96 cents a share, a year earlier. Excluding transactions costs and other adjustments, per-share earnings rose to $1.44 from $1 as revenue surged 37% to $4.3 billion.

Analysts polled by Thomson Reuters were expecting a $1.39 per-share profit on $4.3 billion of revenue.

Gross margin narrowed to 29.5% from 31.6%.

Backlog at the company's rig-technology business reached $10.36 billion as of March 31, up from $10.16 billion at the end of December. New orders in the segment, National Oilwell's largest, rose to $1.91 billion, a 15% increase from its $1.67 billion level a quarter earlier.

Revenue in the rig technology segment jumped 40% from a year ago, while the petroleum services and supplies unit generated 35% higher revenue. Sales from the distribution and transmission segment rose 38%.

Shares closed at $78.02 Tuesday and were inactive premarket. The stock has climbed 15% so far this year.

-By Drew FitzGerald, Dow Jones Newswires; 212-416-2909; Andrew.FitzGerald@dowjones.com

(END) Dow Jones Newswires

April 25, 2012 07:40 ET (11:40 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Pandora/ABG: Mindre sats på kursfald hos hedgefond luner aktiekursen

22-11-2017 15:47:15
Pandora har haft et hårdt 2017 på aktiemarkedet, hvilket er blevet forstærket af, at en håndfuld store investeringsselskaber har shortet aktien og dermed satset på kursfald.Derfor er det positivt for aktiekursen, at den amerikanske hedgefond Maverick Capital har mindsket sin shortposition til 0,97 pct. af aktierne fra tidligere 1,31 pct.- Det er den første større shortreduktion, vi har set gennem ..

Vestas/Sydbank: Vindmølleindustrien risikerer endnu lavere priser

22-11-2017 14:28:26
Priserne på vindmøller har været nedadgående de seneste måneder, og Vestas og de andre aktører i branchen skal ikke forvente, at det værste er overstået.Det vurderer aktieanalytiker Jacob Pedersen fra Sydbank, efter at den seneste store vindauktion i Tyskland blev afgjort med prisfald på 11 pct.- Priserne matcher meget godt den udvikling, vi har set og hørt om fra vindmølleproducenterne, så hvis m..

Novo/dir: Vækst i biofarma er afhængig af tilkøb

22-11-2017 10:07:28
Novo Nordisks ambition om at vende den negative udvikling for selskabets biofarmaforretning, så den atter kan begynde at vokse frem mod 2020, er afhængig af tre dele, herunder opkøb.Det fortalte direktør for Novos bløderdivision, Christian Kanstrup, tirsdag på Novos kapitalmarkedsdag.Salget af Novos blødermiddel Novoseven er under pres fra det konkurrerende blødermiddel Hemlimbra fra Roche, som No..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Genmab, Vestas og Pandora fortsat i fokus
2
Vestas får første russiske ordre nogensinde - NY
3
Vestas/CS: Prisudvikling og arbejdskapital koster på kursmålet - NY
4
Vestas: Ny tysk vindauktion understreger stort prispres
5
Vestas/Sydbank: Vindmølleindustrien risikerer endnu lavere priser

Relaterede aktiekurser

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. november 2017 23:08:45
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171108.1 - EUROWEB3 - 2017-11-22 23:08:45 - 2017-11-22 23:08:45 - 1 - Website: OKAY